After Inhaled insulin failed, we now have buccal, nasal, oral, inhaled and now rectal insulin in studies. Oramed Pharmaceuticals, Inc., a developer of alternative drug delivery systems, announced last week, that it has received approval from the South Africa Medicines Control Council to begin conducting Phase 1A trials on human …

A powerful antioxidant in green tea may prevent or delay the onset of type 1 diabetes, Medical College of Georgia researchers say.

Novo Nordisk is turning to stem cells in the hunt for a cure for diabetes by launching a new collaboration to develop a treatment for type 1 diabetes by programming stem cells to turn into insulin-producing cells.

End-stage renal disease rates rose following widespread introduction of high fructose corn syrup in the American diet, supporting speculation that fructose harms the kidney.

Adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight for Type 1’s.

Novel insulin formulation provides for glucose-regulated insulin delivery.

Dave Kliff, Publisher of Diabetes Investor, recently reviewed the last remaining inhaled insulin in development and has some interesting information. It looks like the hardest part of making it work will be who sells it. Make sure you read, Buying Into The Dream

In a head to head trial (LEAD 6), it showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice daily.

A 2-day in-hospital group program of diabetes education, followed by individual support sessions every 3 months, significantly helped prevent or delay progression to type 2 diabetes in patients with impaired glucose tolerance.

At-risk individuals with an HbA1c test level of 5.4% or greater can signal undiagnosed diabetes and certainly prediabetes, according to new study findings.